PureTech Health (PRTC) Income from Continuing Operations (2023 - 2025)
PureTech Health (PRTC) reported Income from Continuing Operations of 42936000.0 for Q2 2025, up 21.98% year-over-year from 35200048.86 in Q2 2024, and up 29.82% quarter-over-quarter from 61177000.0 in Q4 2024.
PureTech Health (PRTC) Income from Continuing Operations (2023 - 2025) Analysis & Trends
PureTech Health (PRTC) has 3 years of Income from Continuing Operations data on file, last reported at 42936000.0 in Q2 2025.
- Income from Continuing Operations for Q2 2025 came in at 42936000.0, up 21.98% year-over-year; the trailing twelve-month figure through Jun 2025 was 161080000.0 (changed N/A YoY), and the FY2025 annual result was 110085000.0, up 15.77% from the prior year.
- Income from Continuing Operations improved to 42936000.0 in Q2 2025 per PRTC's latest filing, from 61177000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1937000.0 in Q4 2023 and troughed at 61177000.0 in Q4 2024.
- A 3-year average of 40270000.0 and a median of 48983000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 3058.34% in 2024, then advanced 21.98% in 2025.
- A 3-year view of Income from Continuing Operations shows it stood at 1937000.0 in 2023, then plunged by 3058.34% to 61177000.0 in 2024, then advanced by 29.82% to 42936000.0 in 2025.
- Business Quant data shows PRTC's Income from Continuing Operations at 42936000.0 in Q2 2025, 61177000.0 in Q4 2024, and 55030000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -42.94 Mn |
| Dec 31, 2024 | -61.18 Mn |
| Jun 30, 2024 | -55.03 Mn |
| Dec 31, 2023 | -1.94 Mn |